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ABSTRACT: Osteosarcoma is an aggressive form of bone
cancer mostly affecting young people. To date, the most
effective strategy for the treatment of osteosarcoma is the
surgical removal of the tumor with or without combinational
chemotherapy. In this study, we present the development of a
pH-sensitive drug-delivery system in the form of micro-
particles, with increased chemotherapeutic action against the
osteosarcoma cell line SAOS-2, and with reduced toxicity
against the heart myoblastic cell line H9C2. The delivery
system is composed of calcium carbonate and collagen type I,
and is loaded with cerium dioxide (CeO2) nanoparticles (<25
nm) and the anticancer drug doxorubicin. The fabricated microparticles were fully characterized morphologically and
physicochemically, and their ability to induce or inhibit apoptosis/necrosis was assessed using in vitro functional assays and flow
cytometry. The results presented in this study show that the highest concentration (250 μg/mL) of the therapeutic
microparticles (CaCO3-based therapeutic modulators (C-TherMods)), which corresponds to 6.4 μg/mL of encapsulated
doxorubicin, can protect the H9C2 cells even after 120 h, since the percentage of viable cells at this time point is 65%. On the
contrary, when H9C2 cells are treated with 0.5 μg/mL of free doxorubicin, 75% of the cells are dead only after 24 h. When
SAOS-2 cells are treated with the same concentration of C-TherMods (250 μg/mL), the viability of SAOS-2 cells is 80% after
24 h, while it reduces to 50% after 120 h. At pH 6.0, the synergic effect of the pro-oxidant CeO2 nanoparticles and of the
encapsulated doxorubicin leads to almost 100% of cell death, even at the lowest concentration of C-TherMods (50 μg/mL).
■ BACKGROUND
Osteogenic sarcoma (or osteosarcoma) is a form of malignant
tumor that affects mostly young people below the age of 25 and
elderly above the age of 60. It has a 5 year survival rate of 80%,
which is dramatically reduced in the case of metastasis.1−3 The
current treatment for osteosarcoma comprises the use of
chemotherapeutic drugs before the surgical removal of the
tumor (neoadjuvant therapy), as well as after its removal
(adjuvant therapy). The most common chemotherapeutic
agents are doxorubicin (DOX), methotrexate, cisplatin,
ifosfamide, and etoposide, as well as combinations of them.
Although the use of these chemotherapeutics leads to a
significant reduction of the tumor and an increase in the survival
rate of the patients, it also leads to vital side effects, some of
which are alopecia, myelosuppression, mucositis, nausea, and
vomiting. Besides this, deaths due to acute toxicity have also
been reported, especially in the case of DOX. More specifically,
the toxic effects caused by DOX are related to the intensity and
the total cumulative dose that is given to a patient, with a
significant increase in heart failure when the administered dose is
above 550 mg/m2.2,4
Aiming at increasing the therapeutic effect and decreasing the
side effects of the existing chemotherapeutics, various drug-
delivery systems (DDS) based on organic and/or inorganic
materials for the treatment of various types of cancer, as well as
for other diseases, have been developed.5−16 These systems
allow for a better bioavailability, pharmacokinetics, controlled
and sustained release of the encapsulated therapeutic agents, and
specific targeting properties, those overall enhance the
therapeutic efficacy of the administered drugs. Of the inorganic
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materials, the ones that are mostly used for the fabrication of
DDS are gold, silicon, iron oxide, calcium phosphate, and
calcium carbonate (CaCO3).
17
CaCO3 in the form of microparticles, microspheres, and
nanoparticles has been robustly used in drug delivery for the
treatment of various types of cancer, including osteosarcoma,
due to certain attractive characteristics such as its high
biocompatibility, slow biodegradation, osteoconductivity, con-
trolled and sustained release of various chemotherapeutics, and
pH-sensitive properties.17−21
Collagen is one of the main components of the bone, along
with bone minerals made mostly of calcium and phosphate salts.
Collagen-based structures in the form of microspheres,22
hydrogels,23−25 and fibers26,27 find use in many biomedical
applications, such as drug-delivery systems for the treatment of
cancer or applications related to tissue engineering, mostly due
to the high biocompatibility and low immunogenicity that they
present.
Overproduction of reactive oxygen species (ROS) is one of
the main characteristics that cancerous tissues present, and
recently, many studies that demonstrate reduction of malignant
tumors through ROS up- or down-regulation have been
published.28,29 One of the materials that only recently has
been started to be exploited for its dual ability to scavenge and to
generate ROS according to alterations to the pH of the extra-
and intracellular microenvironment is CeO2. CeO2 in the
nanoscale range (e.g., nanoparticles) has the ability to scavenge
ROS when the environmental pH is 7.4, yet generates reactive
oxygen species when the pH is 6, a value close to the one that
cancerous tissues present. This ability makes CeO2 nano-
particles attractive since they can work as a natural bodyguard
for healthy cells while selectively killing cancerous cells. On the
basis of this, a number of studies that make use of CeO2
nanoparticles alone or in combination with other types of
treatments have been presented.30,31
In the scope of this, we hypothesized that the combination of
CeO2 nanoparticles and doxorubicin will reduce the toxicity of
DOX towards healthy cells and will selectively kill cancer cells at
lower pH values. We further hypothesized that the encapsula-
tion of these nanoparticles inside a more stable delivery system
that is not affected by the ionic strength of the microenviron-
ment will increase its stability and release properties, allowing for
an enhanced therapeutic efficacy. Thus herein, we present the
development of pH-sensitive CaCO3-based therapeutic modu-
lators (C-TherMods) with enhanced anticancer properties for
the potential treatment of osteogenic sarcoma. These micro-
particles, which are of spherical morphology, are composed of a
calcium carbonate core and a thin layer of collagen type I, which
acts as a barrier to the burst release of DOX through the C-
TherMods. The C-TherMods which are loaded with CeO2
nanoparticles (<25 nm) and with the anticancer drug DOX,
aim at a reduction of the cytotoxicity on healthy heart cells
(H9C2) and at an enhanced anticancer activity against
osteosarcoma cells (SAOS-2) due to increased ROS generation
at pH 6. The fabricated system was fully characterized
morphologically and physicochemically, and loading and release
studies were performed using high pressure liquid chromatog-
raphy. The in vitro studies demonstrated that the combination
of CeO2 nanoparticles and DOX leads to an enhanced reduction
in the proliferation of osteosarcoma (SAOS-2) cells, while at the
same time protects against the toxicity toward heart cells
(H9C2). The novelty of this study lies in the enhanced
therapeutic activity of the C-TherMods due to the combina-
tional treatment that it provides. Although other studies that
make use of CeO2 nanoparticles and/or DOX have been
published, this is the first time that a system loaded with a
therapeutic combination like the one described above is used,
and that a simultaneous ability of inducing or inhibiting
apoptosis/necrosis due to CeO2 nanoparticles and DOX is
presented.
■ MATERIALS AND METHODS
Materials. All of the materials were purchased from Sigma-
Aldrich unless stated otherwise.
Preparation of CaCO3 Therapeutic Modulators (C-
TherMods). The calcium carbonate therapeutic modulators
(C-TherMods) were fabricated using a simple co-precipitation
method. In the first step, both CaCl2·2H2O (CAS: 10035-04-8)
andNa2CO3 (CAS: 497-19-8) were dissolved in 400 and 300 μL
of distilled water, respectively, while 10 mg of CeO2 nano-
particles (<25 nm) (CAS: 1306-38-3) were dispersed in 100 μL
of a doxorubicin (CAS: 25316-40-9) solution (10 mg/mL) in
water. The dispersion of CeO2 nanoparticles and doxorubicin
were added to the Na2CO3 solution and vortexed for 30 s. The
new dispersion (Na2CO3 + CeO2 nanoparticles + doxorubicin)
was added to the CaCl2 solution under vigorous stirring (1500
rpm) and stirred for 30 s. Then, the dispersion was left to
precipitate for 15 min and subsequently was washed three times
with distilled water. The therapeutic microparticles were
collected by centrifugation at 5000 rpm for 10 s.
The coating of the microparticles was performed at a second
step. After cleaning, a small amount of the microparticles’
dispersion was placed in a preweighted vial and freeze-dried to
calculate the concentration of the dispersion. Then, the loaded
microparticles were placed on a magnetic stirrer under normal
stirring at pH 5.5, and collagen type I at the same pH and at a
final concentration of 1.9 mg/mL was added to the dispersion.
The new dispersion was stirred for 1 h and then the therapeutic
modulators were centrifuged at 5000 rpm for 10 s and washed
three times with distilled water. Then, the sample was freeze-
dried and kept at 4 °C until further use.
Morphological and Physicochemical Characteriza-
tion. Electron Microscopy and Elemental Analysis. The
morphological characterization of the spherical microparticles
was performed using a scanning electron microscope and a
transmission electron microscope.
For the scanning electron microscopy (SEM) analysis, a FEI
200 operating at 15 keV, with beam currents varying from 43 pA
to 0.17 nA, was used. The elemental analysis was performed
using a built-in electron dispersion X-ray analysis detector from
Bruker. All of the samples were coated with gold at 25 mA for 90
s before their study by SEM.
For the transmission electron microscopy (TEM) analysis, a
FEI Tecnai G2 F20 TWIN TMP with a Schottky emitter
operated at 200 kV was used. The energy-dispersive X-ray
spectroscopy (EDS) analyses have been acquired using a Bruker
XFlash 6|T30 silicon drift detector, with 30 mm2 effective area.
Each sample has been sonicated for a few minutes to avoid the
presence of aggregates. The solution (5 μL) has been dropped
onto an ultrathin carbon-coated Cu grid with a sample holder
and a double-tilt analytical holder.
Dynamic Light Scattering (DLS). Dynamic light scattering
measurements were performed using a Zetasizer Nano ZS90 of
Malvern Instruments. The measurements before and after the
collagen coating were carried out at 25 and 37 °C, and the
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conductivity was adjusted in the range of 30−100 μS/cm using
ultrapure water at a pH 5.5, to have comparable results.
The ζ potential values represent mean ± standard deviation
(SD) of three different measurements and with 17 runs in each
measurement. Before each acquisition, the samples were
sonicated for ∼10 s using a Bandelin ultrasonic probe at 8 W
to avoid the presence of aggregates.
Fourier Transform Infrared (FT-IR) Spectroscopy. Infrared
spectroscopy was performed using a Shimadzu Miracle 10.
Before the measurements, all of the samples have been freeze-
dried. The number of scans was set to 45, the scanning range was
set from 4000 to 400 cm−1, and the resolution step was 4 cm−1.
The graphs were plotted using OriginPro software 9.1.
X-ray Photoelectron Spectroscopy (XPS) Analysis. XPS
measurements were performed on a Kratos Axis Ultra DLD
spectrometer using a monochromatized Al Kα source operating
at 15 kV and 20 mA. Wide scans were acquired at an analyzer
pass energy of 160 eV, while high-resolution narrow scans were
performed at a constant pass energy of 10 eV and steps of 0.1 eV.
The photoelectrons were detected at a takeoff angleΦ = 0° with
respect to the surface normal. The pressure in the analysis
chamber was maintained below 7 × 10−9 Torr for data
acquisition. The data were converted to VAMAS format and
processed using CasaXPS software, version 2.3.17. Data analysis
on the Ce 3d energy region was performed to assess Ce(III) and
Ce(IV) contents, following the method described in a previous
study of our group.32
Inductively Coupled Plasma (ICP) Analysis. Inductively
coupled plasma (ICP) atomic emission spectroscopy (AES) was
performed using an iCAP 6500 Thermo spectrometer. All
chemical analyses performed by ICP-AES were affected by a
systematic error of about 5%. Samples were dissolved in HCl/
HNO3 3:1 (v/v).
Loading and Release Studies. The loading and release
studies were performed using a high-performance liquid
chromatograph (HPLC) Shimadzu LC-20AT. The chromato-
graphic separation was carried out using a C-18 column (150
mm × 4.6 mm i.d., 5 μm particle size). The mobile phase
consisted of acetonitrile and water (containing acetic acid 1%)
and pumped in dynamic mode (gradient: ACN 15%-5 min,
25%-10 min, 50%-15 min, 75%-20 min) with a flow rate of 0.5
mL/min. The elution of the analyte was monitored at 480 nm.
The standard curve was prepared by dissolving 1 mg of DOX in
1 mL of the mobile phase and filtered using a 0.2 μm syringe
filter. A concentration range of 10−1000 μg/mL was obtained
upon further serial dilution.
Antioxidant Capacity. The antioxidant ability of the final
system (C-TherMods) was assessed using a total antioxidant
capacity kit from Sigma-Aldrich according to manufacturer’s
instructions. Various concentrations of C-TherMods (50, 125,
and 250 μg/mL) were tested, and the results were compared to
the antioxidant capacity of Trolox, an analog of vitamin E.
In Vitro Studies. Cell Lines. In this study, two different cell
lines were used, the osteogenic sarcoma cell line SAOS-2
(ATCCHTB-85) and the rat myoblastic cell line H9C2 (ATCC
CRL-1446). Both cell lines were cultured in T75 flasks using
high-glucose Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 1% penicillin/
streptomycin, and 1% L-glutamine, and at normal culture
conditions (37 °C, 5%CO2). For all of the experiments, the used
cells were between passage 10 and passage 20. The medium
during culture was changed every 2 days.
Metabolic Activity and Proliferation Assays. Upon 80% of
confluence in a T75 flask, both cell lines were detached using
trypsin 0.25% and seeded at a density of 25 × 103 cells/cm2 in a
24-well tissue culture plate, with 500 μL of the same medium
used for the culturing. After 48 h, the cells were treated with
various concentrations of free doxorubicin (0.5, 1.0, 1.5, 3.0, and
6.0 μg/mL), free CeO2 nanoparticles (12.5, 25, and 50 μg/mL),
a combination of CeO2 nanoparticles (50 μg/mL) and of the
aforementioned doxorubicin concentrations, and with C-
TherMods (50, 125, and 250 μg/mL). For H9C2, the pH of
the used medium for all of the treatments was 7.4, while for
SAOS-2, two different media, one at pH 7.4 and one at pH 6.0,
were used. To assess the effect of each treatment on the cell
metabolic activity and proliferation, a WST-1 assay (Sigma-
Aldrich) and a Quant-iT PicoGreen dsDNA Assay Kit
(Invitrogen) were used, respectively, according to the
manufacturers’ instructions. For the PicoGreen Assay Kit, 200
μL of Milli-Q ultrapure water was added to the cells, followed by
scraping. The cell dispersion was frozen at −80 °C, and after
three freeze−thaw cycles, a predetermined amount of the
dispersion was used for DNA quantification. Sample fluo-
rescence was measured using a PerkinElmer (Victor 2030) plate
reader at λex = 480 nm and λem = 520 nm.
Internalization Studies. To evaluate C-TherMods internal-
ization, H9C2 and SAOS-2 cells were seeded on Ibidi 35 mm
cell imaging Petri dishes and preincubated for 24 h with 100 μg/
mL of particles in full supplemented media. After 24 h, the cells
were washed two times with phosphate-buffered saline (PBS)
solution and then fixed for 20 min at 4 °C with
paraformaldehyde (4% in PBS). After the fixation, the cells
were incubated for 30 min at room temperature with a blocking
solution of goat serum (10% in PBS) and then stained for 30min
at 37 °C with a mixture of Oregon Green 488 Phalloidin 0.165
μM (Thermo Fisher) and Hoechst solution 5 μg/mL
(Invitrogen). After staining, the cells were washed two times
with PBS. The internalization of C-TherMods by cells was
studied using confocal laser scanning microscopy on a Nikon
C2+ system (actin filament in green λex = 488 nm, λem = 525 nm;
C-TherMods in red λex = 561 nm, λem = 585 nm; nuclei in blue
λex = 401 nm, λem = 447 nm). Three-dimensional (3D)
rendering of z-stacks was performed by using NIS-Elements
software (Nikon).
Assessment of Apoptosis/Necrosis. At predetermined time
points (24, 72, and 120 h post-treatment), H9C2 and SAOS-2
(at pH 7.4 and 6.0) were trypsinized and incubated with annexin
V-fluorescein isothiocyanate (FITC)/propidium iodide (PI)
(Thermo Fisher) for viability, apoptosis, and cell death
assessment by flow cytometry. Briefly, at each time point, cells
were washed with Dulbecco’s phosphate-buffered saline
solution without calcium and magnesium and detached using
trypsin−ethylenediaminetetraacetate (0.05%). A total of 100 ×
103 cells per tube were stained with 2.5 μMannexin V-FITC and
1 μg/mL PI in annexin V binding buffer (1×) for 15 min at 37
°C protected from light. Cells stained with annexin V-FITC/PI
were evaluated using a Beckman Coulter cytoflex. Live cells
(annexin V−/PI−), apoptotic cells (annexin V+/PI−), and
dead cells (PI+) were analyzed using Cytoflex software
(Beckman Coulter). Untreated cells were used as controls.
■ RESULTS AND DISCUSSION
Morphological Characterization and Elemental Anal-
ysis. Calcium carbonate microspheres have been robustly used
as antioxidant and/or as anticancer drug-delivery systems due to
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many advantages, including easy fabrication and pH-sensitive
properties. However, although many studies related to CaCO3-
delivery systems loaded with antioxidant or anticancer drugs
have been presented to date,13,17,33 there has not been a study
demonstrating that a calcium carbonate-based system can act as
a modulator of oxidative stress and subsequently as a therapeutic
modulator, by protecting healthy cells and killing cancer cells
depending on the pH of the extracellular environment. In this
study, we tried to combine the advantages of a calcium
carbonate-delivery system with versatile CeO2 nanoparticles,
which can act as a pro-oxidant or as an antioxidant agent
depending on the extracellular pH, and we also enhanced the
therapeutic efficacy of our carrier toward osteosarcoma cells, by
loading this carrier with the anticancer drug doxorubicin. In the
final step, we coated the fabricated system with collagen aiming
at attaching to the system a biomimetic character that mimics
the bone environment.
After the synthesis, the first study that we performed was the
morphological assessment of the calcium carbonate micro-
particles loaded with CeO2 nanoparticles and doxorubicin and
coated with collagen type I (hereafterin called C-TherMods),
and this was carried out using transmission and scanning
electron microscopy techniques. From the TEM and SEM
images (Figures 1 and S1A in the Supporting Information), it
can be seen that the microparticles consist of smaller particles
creating a larger structure with a rough surface and an average
size of 0.75 ± 0.25 μm (mean value of 100 particles). From the
transmission electron micrograph, the presence of CeO2
nanoparticles on the surface of C-TherMods is evident, and
according to the XPS analysis presented in Figure S1B, the
percentage of cerium (Ce) on the surface of the microparticles is
4.81% (other elements: C 47.44%, O 39.94%, Ca 7.17%, Na
0.64%). ICP analysis showed that the total percentage of Ce in
the whole structure of C-TherMods is 17.70% (Ca: 36.80%).
Mapping of the elements by energy-dispersive X-ray spectros-
Figure 1. (A) Transmission electron micrograph of a C-TherMod and (B) EDS mapping of the elements that comprise C-TherMods (top right: Ca;
bottom left: Ce; bottom right: O). The scale bar is 200 nm.
Figure 2. (A) ζ potential measurements of plain CaCO3microparticles (ζ =−20.90± 2.12 mV, cond. = 36.7 μS/cm) and C-TherMods (ζ = +11.80±
5.91 mV, cond. = 67.3 μS/cm) and (B) FT-IR spectra of plain CaCO3 (spectrum a), CaCO3 loaded with CeO2 nanoparticles (spectrum b), free CeO2
nanoparticles (spectrum c), and C-TherMods (spectrum d).
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copy (EDS, Figures 1 and S1A) and the EDS images presented
in Figure S1C prove the homogeneous deposition of CeO2
nanoparticles on the whole surface of the microparticles.
Physicochemical Characterization. To prove the suc-
cessful coating with collagen as well as to further confirm the
presence of CeO2 nanoparticles, we performed dynamic light
scattering measurements and Fourier transform infrared spec-
troscopy.
The ζ potential measurements demonstrated a negative
surface charge (ζ) of the microparticles (−20.90 ± 2.12 mV)
before collagen coating, while after the coating, a shift toward
positive values (+11.80 ± 5.91 mV) was observed, suggesting
that collagen was successfully deposited on the surface of the
CaCO3 microparticles. This positive surface charge can be
attributed to the amine and carboxylic groups of collagen, which
at a slightly acidic pH (5.5) are protonated giving a positive ζ
potential. The data presented in Figure 2A represent the average
of three measurements at 25 °C, but similar results were also
acquired when the temperature was increased at 37 °C.
Due to the fact that the CeO2 nanoparticles on the surface of
the microparticle may also affect the surface charge of the C-
TherMods, we also performed infrared spectroscopy as a
complementary technique to verify the presence of collagen.
The data illustrated in Figure 2B present the spectra of (a) plain
calcium carbonate microparticles (CaCO3), (b) calcium
carbonate microparticles loaded with CeO2 nanoparticles
(CaCO3 + CeO2), (c) commercial CeO2 nanoparticles, and
(d) collagen-coated calcium carbonate microparticles loaded
with CeO2 nanoparticles and DOX (C-TherMods). The strong
broad peak at 1400 cm−1 in spectra (a), (b), and (d)
corresponds to the v3 asymmetric vibration of CO3.
34 The
peak at 1648 cm−1 in spectrum (d) can be attributed to the
amide I (N−H) bond of collagen, while the peak at 1077 cm−1
corresponds to ν(C−O) and ν(C−O−C) absorptions of the
carbohydrate moieties.35 The peaks of CeO2 in spectrum (c)
(ca. 555 cm−1, magnified spectrum) cannot be seen in spectrum
(d) due to the weak signal that CeO2 provides and due to the fact
that these vibrations are covered by the strong vibrations of
calcium carbonate at 1400 cm−1. A magnified image of the peaks
of CeO2 (spectrum c) is also given in the inlet of Figure 2B,
aiming at making more clear the presence of CeO2 nanoparticles
on C-TherMods.
The antioxidant ability of C-TherMods was finally studied
and it was found that 50, 125, and 250 μg/mL of C-TherMods
are equivalent with 20.0, 42.5, and 47.5 nmol of Trolox,
respectively, proving their ability to scavenge ROS.
Loading and Release Studies. The dynamic loading, the
encapsulation efficiency, and the release profiles of DOX
encapsulated in C-TherMods at three different pH values (7.4,
6.0, and 4.5) were assessed by HPLC. From these studies, it was
found that the encapsulation efficiency of C-TherMods is 88.40
± 3.80%, while the dynamic loading was 2.56 ± 0.50%. The
encapsulation efficiency values are close to other similar systems
reported in the literature, where DOX is encapsulated inside
calcium carbonate microparticles without any coating36 or with
a biomimetic coating,37,38 as well as in systems where DOX is
conjugated with CeO2 nanoparticles.
39
The release profile of DOX that is presented in Figure 3,
demonstrates a controlled and sustained release over time,
which depends on pH. At pH 7.4, the cumulative release of DOX
reaches up to 18% after a period of 8 days, while this percentage
is increased (35%) when the pH is reduced to 6.0 and further
increases to 63% when the pH is further reduced to 4.5. It has to
be noted that compared to other systems in the literature,37 C-
TherMods do not present a burst release in the first few hours
inside the medium. This behavior may be attributed not only to
the collagen layer around C-TherMods that is partially
responsible for the slow release of DOX, but also due to
potential electrostatic interactions between CeO2 nanoparticles
and DOX that further enhance this sustained release. It is also
noteworthy that compared to other similar works in the
literature, the release of DOX is slow and sustained when pH
is 7.4, while it has a dramatic release when pH is 4.5. For
example, Kamba et al. presented an 80% release of DOX at pH
7.4 after 20 h,36 while Bosio et al.38 and Dong et al.37 presented
at pH 7.4 a 50 and an 18% release after 24 h, respectively. During
the release of DOX at lower pH, although the results
demonstrated that the release behavior is similar to other
systems, our system demonstrated a more controlled release
depending on the pH, suggesting its appropriateness for
controlled and sustained drug delivery.
When the pH is acidic, three parameters affect the release of
DOX from the C-TherMods. The first one is the electrostatic
interactions between amine and carboxylic groups of collagen,
which start to protonate due to the low pH, leading to repulsion
between the functional groups and potentially create some free
space that allows the drug to be released. Secondly, the
degradation of CaCO3 at low pH also affects the release profile,
while thirdly, as aforementioned, an increased release can also be
potentially attributed to the alterations of the electrostatic
interactions between CeO2 nanoparticles and DOX.
Internalization Studies. Confocal microscopy was used to
assess the ability of SAOS-2 and H9C2 to internalize the C-
TherMods. The confocal images presented in Figure 4 prove
that C-TherMods can be internalized from both cell lines after a
period of 24 h. Complementary results from confocal
microscopy can also be found in the Supporting Information
(Figure S2).
Effect of Doxorubicin, CeO2 Nanoparticles, and C-
TherMods on Cell Proliferation. C-TherMods represent a
stimuli-responsive and versatile system, the therapeutic ability of
which depends on various constituents and conditions. In view
of this, we assessed the effect of these various constituents on cell
metabolic activity (Figure S3 in the Supporting Information)
Figure 3. DOX release profiles from of C-TherMods acquired through
HPLC at different time points (1, 4, 24, 72, 120, and 192 h) and at
different pH values (4.5, 6.0, and 7.4) at 37 °C (data are presented as
mean ± SD).
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and proliferation (Figure 5) independently, aiming at under-
standing how our system works. SAOS-2 was selected as an in
vitro model for osteogenic sarcoma, and two different pH values
were used, aimed at imitating the extra/intracellular pH of the
environment of the tumor tissue. In addition, since the use of
doxorubicin has been related to several side effects including a
significant increase in heart failure depending on the
administered dose, we used H9C2 as an in vitro model for
studying the effect of C-TherMods on cardiac tissue. The results
that are presented below as well as in the Supporting
Information demonstrate that C-TherMods are not only able
to kill cancer cells, but also in tandem protect H9C2 cells from
the toxicity of doxorubicin.
It is evident from the graphs in Figure 5A−C that C-
TherMods demonstrate a protective effect toward H9C2 in
comparison to SAOS-2 (pHs 7.4 and 6.0) even at the lowest
concentration for the first 24 h. The same protective effect can
also be seen for the time points of 72 and 120 h (Figure 5A),
although significantly different compared to the 24 h time point.
The proliferation rate of H9C2 cells is reduced probably due to
the release of doxorubicin that affects also the metabolic activity
of H9C2. The proliferation rate of SAOS-2 at 72 h at both pH
values (Figure 5B,C) is higher than the proliferation rate of
H9C2, and this can be attributed to the fact that SAOS-2 are
proliferating with a higher rate giving a higher proliferation
compared to H9C2. This peculiarity can be seen only at the
concentrations of 50 and 125 μg/mL of C-TherMods, probably
due to the lower concentration of the encapsulated doxorubicin,
while at the concentration of 250 μg/mL, the proliferation rate is
similar for all cell types (Figure 5A−C, 250 μg/mL). At 120 h, it
is more evident that C-TherMods at concentrations of 125 and
250 μg/mL provide higher protection to H9C2 (cell
proliferation ∼65%) in comparison to SAOS-2 at pH 7.4 (cell
proliferation∼50%) and to SAOS-2 at pH 6.0 (cell proliferation
∼55%); for statistical significance, please see the corresponding
figures. The presented results are in close agreement with the
work of Zhao et al.,33 in which a calcium carbonate/
doxorubicin@silica nanoreactor was fabricated. In this study,
the pH-dependent release of DOX affected the proliferation of
HeLa cells in a dose- and time-dependent manner, resulting in
an 80% reduction in cell proliferation after 24 h when 5 μg/mL
of DOX was used and in a 40% reduction when DOX was
encapsulated inside the proposed nanoreactor. These results are
similar to the ones presented in this work, and more specifically
with the results presented in Figure 5B (24 h) for 250 μg/mL of
C-TherMods (corresponding to 6.4 μg/mL of free DOX) at pH
7.4, and with the results for free DOX that are presented in
Figure 5H (3 and 6 μg/mL).
CeO2 nanoparticles are well known for their enzyme-like
activity, which allows them to act as a pro-oxidant (ROS
generation) or as an antioxidant (ROS scavenging) depending
on the pH. Taking into consideration this characteristic, and
wanting to relate this property to the ability of C-TherMods to
protect H9C2 cells and kill cancerous cells, we performed
metabolic activity and DNA proliferation assays using various
concentrations of CeO2 nanoparticles. From the graphs
depicted in Figure 5D−F, as well as from the graphs of
metabolic activity (Figure S3D−F in the Supporting Informa-
tion), it can be seen that CeO2 nanoparticles do not have an
effect either on the metabolic activity or on the proliferation of
any of the treated cell lines. It was expected that CeO2
nanoparticles at pH 6.0 would generate more ROS leading to
a ROS-mediated apoptosis and to a reduction in the
proliferation of SAOS-2, but as presented in Figure 5F, this is
not evident. Two possible reasons can be hypothesized for the
lack of any effect. The first reason is that CeO2 nanoparticles at
pH 6.0 do not generate a high amount of ROS capable of leading
to ROS-mediated apoptosis, and the second one relies on a
possible ability of SAOS-2 to scavenge the overproduced ROS.
The high proliferation rate of SAOS-2 even at pH 6.0 leads to a
high metabolic activity (Figure S3F in the Supporting
Information) and an increased cell number, which can be
responsible not only for increased ROS production, but also for
increased ROS scavenging. Both the increased cell number due
to high proliferation and the increased ROS scavenging support
our aforementioned hypothesis.
In contrast to CeO2 nanoparticles, doxorubicin presents
cytotoxicity even at the lowest used concentration of 500 ng/mL
(Figures 5G−I and S3G−I in the Supporting Information).
According to the loading studies, the dynamic loading of
doxorubicin is 2.56%, meaning that 50, 125, and 250 μg/mL of
C-TherMods correspond to 1.28, 3.20, and 6.40 μg/mL of free
doxorubicin. Comparing the results between free doxorubicin
(Figures 5G−I and S3G−I in the Supporting Information) and
C-TherMods (Figures 5A−C and S3A−C in the Supporting
Information), it is pretty evident that C-TherMods provide
protection toward H9C2 cells and a controlled cytotoxic effect
over time toward SAOS-2 at pH values of 7.4 and 6.0 and at
Figure 4. Internalization of C-TherMods (100 μg/mL) by (A) SAOS-2 and (B) H9C2 cells after 24 h of treatment (C-TherMods in red, F-actin in
green, nuclei in blue).
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concentrations of 125 and 250 μg/mL (comparison between
Figure 5A−C and 5G−I at 120 h and corresponding figures for
metabolic activity, Figure S3A−C and S3G−I; for statistical
significance, please see the corresponding figures).
To enhance our hypothesis concerning the protective role of
CeO2 nanoparticles inside C-TherMods, we have treated both
SAOS-2 cells at pH values of 7.4 and 6.0 and H9C2 cells at pH
7.4 with C-TherMods that do not contain CeO2 nanoparticles.
Figure 5. Proliferation of SAOS-2 and H9C2 cells after treatment with various concentrations of C-TherMods (A−C), CeO2 nanoparticles (D−F),
DOX (G−I), and a combination of CeO2 nanoparticles and DOX (J−L) at different time points and at different pH values. Statistical analysis was
performed using one-way analysis of variance, *n = 3, p < 0.05.
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Both the metabolic activity and the proliferation assays that are
presented in the Supporting Information (Figure S4) show that
even at the lowest concentration of C-TherMods (50 μg/mL)
after 24 h, the metabolic activity of H9C2 cells is reduced to 75%
(Figure S4A), while the cell proliferation (Figure S4D) is
reduced to 30%, in contrast to C-TherMods that contain CeO2
Figure 6.Bar graphs presenting% of live (black), necrotic (red), and apoptotic (blue) cells inH9C2 (A−C) and SAOS-2 cultures at pH 7.4 (D−F) and
at pH 6.0 (G−I), after treatment with free DOX, a combination of CeO2 nanoparticles + DOX, and C-TherMods for 24, 72, and 120 h. The samples
coded as CTRL refer to untreated samples at 24 h, correspondingly for each condition (H9C2 at pH 7.4, SAOS-2 at pH 7.4, and SAOS-2 at pH 6.0).
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nanoparticles where the corresponding metabolic activity
(Figure S3A) and the cell proliferation (Figure 5A) are 100%.
It has to be noted that this difference in both the metabolic
activity and cell proliferation can also be attributed to the
different release profiles of DOX. As it is aforementioned, the
release of DOX is also affected by the electrostatic interactions
between CeO2 nanoparticles and DOX, resulting in different
release profiles in the presence or absence of CeO2 nano-
particles. In the case of SAOS-2, a higher decrease in both
metabolic activity (Figure S4B,C) and cell proliferation (Figure
S4E,F) is observed after 24 h compared to the group where cells
were treated with C-TherMods containing CeO2 nanoparticles
(Figures 5B,C and S3B,C). This behavior can be attributed to
the faster release of DOX from C-TherMods, since as we
mentioned before, the absence of CeO2 nanoparticles possibly
affects the release behavior. The protective role of CeO2
nanoparticles inside C-TherMods is mostly evident after 72 h,
when the cell proliferation in H9C2 is increasing with the
concentration of C-TherMods if CeO2 nanoparticles are
encapsulated (Figure 5A), while decreasing with the increasing
concentration of C-TherMods if CeO2 nanoparticles are not
used (Figure S4E). After 72 h, both H9C2 and SAOS-2 cells are
dead probably due to the increased release of DOX.
Since CeO2 nanoparticles did not present any cytotoxic effect
even at the highest concentration of 50 μg/mL, and since
doxorubicin presented a high cytotoxic effect even at the lowest
concentration of 500 ng/mL, we decided to assess the effect that
the combination of CeO2 nanoparticles and doxorubicin can
have. The results presented in Figures 5J−L and S3J−L
demonstrate that the combination of CeO2 nanoparticles and
doxorubicin can have a protective effect as well as a cytotoxic
effect depending on time and pH. In the case of H9C2 cells
(Figure 5J), it is pretty evident that for the time point of 24 h and
for concentrations of doxorubicin up to 1.5 μg/mL, CeO2
nanoparticles can protect H9C2 cells. This protective effect
can be attributed to the scavenging of overproduced ROS.
Doxorubicin mechanism of action relies on the intercalation and
inhibition of macromolecular anabolism, which stops the
process of DNA replication. Along with this inhibition,
doxorubicin can lead to cell apoptosis through ROS over-
production and a subsequent ROS-mediated apoptosis. We
hypothesize that the protective effect that can be seen when
CeO2 nanoparticles and doxorubicin are combined is due to the
fact that CeO2 nanoparticles (ROS scavengers) counteract
doxorubicin cytotoxic effect by reducing the ROS-mediated
apoptosis. Although we cannot know the exact mechanism of
action, the data presented in Figure 5J−L support our claims. At
low doxorubicin concentrations, the protective effect is more
evident and mostly for the H9C2 cells. When the concentration
of doxorubicin is higher than 1.5 μg/mL, CeO2 nanoparticles
cannot protect H9C2 cells, thus leading to cell death (Figure 5J).
The same protective effect can be seen also after 72 and 120 h
(Figure 5J) with respect to free doxorubicin (Figure 5G).
Comparing these data to the data about SAOS-2 at pH 7.4
(Figure 5K) and SAOS-2 at pH 6 (Figure 5L), we see that the
protective effect of CeO2 nanoparticles is not so evident in these
cases. One possible reason for this is the pH value of SAOS-2
cultures: in the case of SAOS-2 at pH 6.0, we can assume that
this slightly acidic pH either increases the ability of CeO2
nanoparticles to produce ROS or reduces their ability to
scavenge ROS.
Flow CytometryApoptosis Studies. Flow cytometry
was used as a complementary technique to assess the ability of
C-TherMods to induce and/or to inhibit apoptosis. The results
that are presented in Figure 6 and in Figure S5/Table S1 in the
Supporting Information are in agreement with the results that
were acquired using the dsDNA-based cell proliferation assay kit
and that were analyzed above.
For the H9C2 cell line, it can be seen that the use of free DOX
even at the lowest concentration of 0.5 μg/mL for 24 h (Figure
6A) leads to the death of H9C2 cells, with 65% of the cell
population being necrotic and 7% being in the early apoptotic
stage. As the concentration of DOX increases, the number of
dead cells also increases to 80 and 95% for 1.0 and 1.5 μg/mL,
respectively. When DOX is combined with CeO2 nanoparticles
at a concentration 50 μg/mL, it can be seen that the percentages
of dead (necrotic) cells at 24 h are reduced to 49, 52, and 45%,
for 0.5, 1.0, and 1.5 μg/mL, respectively, while the percentage of
early apoptotic cells remains in the range of 7−10% (Figure 6A).
This protective effect, as we pointed out in the previous
paragraph, can be attributed to the therapeutic effect of CeO2
nanoparticles. This protective effect is much higher when C-
TherMods are used, not only due to the encapsulated CeO2
nanoparticles, but also because of the slow release of
doxorubicin, since at 24 h only 15% of DOX is released.
Increased concentration of C-TherMods leads to an increased
number of live cells, with 72, 81, and 85% viability for
concentrations of 50, 125, and 250 μg/mL, respectively (Figure
6A). For these C-TherMods concentrations, the necrotic cells
are, respectively, 13, 6, and 3%, while the early apoptotic cells are
16, 13, and 12%. The reason why early apoptosis is more evident
in the cells treated with C-TherMods compared to free DOX
and to the combination of CeO2 nanoparticles and DOX, is
attributed to the lower concentration of DOX that is
released from the C-TherMods, allowing a better observation
of apoptosis. After 72 h (Figure 6B), the majority (∼90%) of
H9C2 cells treated with free DOX are dead, while a small
percentage (∼23%) of the cells is alive when CeO2 nanoparticles
are used in combination with DOX. The viability of the cells is
significantly higher when C-TherMods are used, presenting
more than 50−60% viable H9C2 cells. After 120 h, the
protective effect of C-TherMods is evident mostly at the highest
concentration (250 μg/mL) of C-TherMods, where the viable
cells remain at 65%, while for the lower concentrations the
viability ranges approximately to 35% (Figure 6B).
In Figure 6D−F, results concerning SAOS-2 cells are
different. When SAOS-2 cells are treated with free DOX or
with the combination of CeO2 nanoparticles + DOX, the
majority of the cells is dead even at 24 h. When the SAOS-2 cells
are treated with C-TherMods, the percentage of viable cells
remains at 80% when the lowest concentration of C-TherMods
(50 μg/mL) is used, ranges from 40 to 55% when 125 μg/mL is
used, and reduces from 80% (24 h) to 50% (120 h) when 250
μg/mL are used. These results suggest that the cytotoxic effect of
C-TherMods affects SAOS-2 cells in a dose-dependent manner,
and also that this cytotoxicity is related to the controlled release
of DOX. In addition, the DOX-related cytotoxicity can be
counteracted by the protective ability of CeO2 nanoparticles at
pH 7.4, where they act as an antioxidant protecting the cells from
ROS-mediated apoptosis. Finally, when the pH of the media is
reduced to 6.0 (Figure 6G−I), 100% of the cells die after 24 h
even after treatment with the lowest concentration of free DOX,
CeO2 nanoparticles + DOX, and C-TherMods. In these
conditions, C-TherMods do not present any protective effect,
and this could be attributed to the fact that CeO2 nanoparticles
start to act as pro-oxidants, leading to increased ROS and
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enhancing the cytotoxic effect of the fabricated system through a
combinatory ROS-mediated and DOX-mediated apoptosis.
This hypothesis is supported by the work of Das et al.,39 who
present an enhanced antitumor effect against three different
ovarian cancer cell lines when CeO2 nanoparticles and DOX are
combined, as well as by the work of Alpaslan et al.,31 where it was
demonstrated that a pH value around 6 enhances the
cytotoxicity of CeO2 nanoparticles and subsequently increases
cell death in bone cancer cells, compared to physiological (7.0)
and basic (9.0) pH values. It has to be noted that pH 6.0 is also
affecting the viability of the cells, and this slightly acidic pH
contributes to the increased cytotoxicity.
■ CONCLUSIONS
Herein, pH-responsive microparticles loaded with the anti-
cancer drug doxorubicin and CeO2 nanoparticles, and coated
with collagen type I, were fabricated. These microparticles (C-
TherMods) were fully characterized morphologically and
physicochemically using several complementary material
characterization techniques. The loading ability and the release
profile of C-TherMods were assessed at various pH values, and it
was found that C-TherMods can release DOX in a pH-
dependent manner and over a period of time of more than 8
days. The in vitro studies using functional assays and the
apoptosis/necrosis studies using flow cytometry demonstrated
that C-TherMods have a protective effect toward the H9C2
heart myoblast cell line, and this protective effect could be
attributed to the slow pH-dependent release of DOX as well as
to the protective effect of CeO2 nanoparticles. When C-
TherMods were used to treat SAOS-2 at pH 7.4, it was found
that their cytotoxic effect was dose-dependent, and after 120 h,
the highest concentration of C-TherMods (250 μg/mL) led to a
reduction of viable cells from 80% (24 and 72 h) to 51% (120 h).
The protective effect of C-TherMods ceased to exist when the
pH of the medium was reduced to 6, suggesting that the
encapsulated CeO2 nanoparticles started acting as pro-oxidants,
enhancing in this way the cytotoxic effect of the C-TherMods by
inducing cell death through a combination of ROS-mediated
and DOX-mediated apoptosis.
The above-presented results suggest that the fabricated C-
TherMods can act as novel stimuli-responsive therapeutic
modulators able to protect specific cell lines (e.g., H9C2) and at
the same time to kill the cancerous ones (e.g., SAOS-2).
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